Dear TrueMed Community,
As we close out an incredible year, I wanted to take a moment to reflect on our journey in 2024—a year defined by collaboration, innovation and growth.
This year, TrueMed forged meaningful partnerships to expand our reach and capabilities. Notably, our collaboration with a top global pharmaceutical company is already enhancing medication safety, leveraging our advanced AI technology to combat counterfeits in real time. These efforts align with our mission: protecting patients and ensuring that what they rely on is exactly what it claims to be. On the technology front, we launched our AI-driven Digital Forensic Lab this year. This cutting-edge platform is transforming how counterfeit investigations are conducted, providing high volume throughput, instant verification and actionable insights. It’s a game-changer not just for our clients but for the broader fight against counterfeits. Lastly, I am proud to share that TrueMed achieved strong growth this year, an accomplishment made possible by the trust our partners place in us and the unwavering commitment of our team. We also had the privilege of onboarding several top 10 global pharmaceutical clients, a testament to the impact of our solutions in safeguarding the integrity of medicines worldwide.
Throughout the year, we’ve also sought to educate and inform through our blog and other platforms, sharing insights on the dangers of counterfeit pharmaceuticals, the early warning signs of counterfeiting, and the critical role of returns and diversions in combating the issue.
As we look ahead to 2025, I’m energized by the opportunities before us. We remain committed to innovating and advancing our technology, deepening our partnerships, and leading the charge in the fight against counterfeit medicines. Together, we are building a safer future for patients and consumers worldwide.
Thank you for being part of this journey. Here’s to another year of growth and impact.
Warm regards,
Jyrki Berg
CEO, TrueMed